Latest Insider Transactions at Kymera Therapeutics, Inc. (KYMR)
This section provides a real-time view of insider transactions for Kymera Therapeutics, Inc. (KYMR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kymera Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kymera Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 06
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
100,000
+2.38%
|
$1,900,000
$19.25 P/Share
|
|
May 05
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
150,000
+3.38%
|
$2,850,000
$19.6 P/Share
|
|
May 04
2022
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.15%
|
$20,000
$1.7 P/Share
|
|
May 03
2022
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.75%
|
$40,000
$2.08 P/Share
|
|
May 03
2022
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.83%
|
$40,000
$2.08 P/Share
|
|
Mar 01
2022
|
Elaine Caughey Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+50.0%
|
-
|
|
Mar 01
2022
|
Jared Gollob Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,600
+25.27%
|
-
|
|
Mar 01
2022
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+24.58%
|
-
|
|
Jan 31
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
34,408
+1.03%
|
$1,376,320
$40.7 P/Share
|
|
Jan 27
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
95,901
+2.83%
|
$3,644,238
$38.33 P/Share
|
|
Jan 24
2022
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
272,767
+7.92%
|
$10,092,379
$37.76 P/Share
|
|
Jan 14
2022
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+26.66%
|
$20,000
$2.08 P/Share
|
|
Jan 14
2022
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.03%
|
$20,000
$2.08 P/Share
|
|
Jan 12
2022
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-18.23%
|
$780,000
$52.2 P/Share
|
|
Jan 12
2022
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+31.57%
|
$30,000
$2.08 P/Share
|
|
Jan 12
2022
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,612
-0.45%
|
$447,824
$52.64 P/Share
|
|
Jan 12
2022
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,612
+1.76%
|
$17,224
$2.08 P/Share
|
|
Jan 11
2022
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,923
-1.16%
|
$913,842
$54.38 P/Share
|
|
Jan 11
2022
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,923
+3.34%
|
$33,846
$2.08 P/Share
|
|
Jan 10
2022
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
22,465
-1.15%
|
$1,190,645
$53.8 P/Share
|
|
Jan 10
2022
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,465
+4.34%
|
$44,930
$2.08 P/Share
|
|
Dec 16
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+1.67%
|
$16,000
$2.08 P/Share
|
|
Dec 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-13.25%
|
$540,000
$54.23 P/Share
|
|
Dec 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+26.66%
|
$20,000
$2.08 P/Share
|
|
Nov 23
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.69%
|
$20,000
$2.08 P/Share
|
|
Nov 02
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,996
-14.36%
|
$944,748
$63.58 P/Share
|
|
Nov 02
2021
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,996
+27.44%
|
$29,992
$2.08 P/Share
|
|
Nov 01
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
42,497
-21.53%
|
$2,592,317
$61.85 P/Share
|
|
Nov 01
2021
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,607
+15.32%
|
$24,607
$1.7 P/Share
|
|
Oct 11
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,456
-0.69%
|
$348,624
$54.04 P/Share
|
|
Oct 11
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,456
+1.35%
|
$12,912
$2.08 P/Share
|
|
Oct 08
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,544
-1.41%
|
$2,409,552
$58.52 P/Share
|
|
Oct 08
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,544
+7.59%
|
$83,088
$2.08 P/Share
|
|
Sep 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-33.19%
|
$600,000
$60.28 P/Share
|
|
Sep 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
10,000
-36.69%
|
$20,000
$2.08 P/Share
|
|
Aug 27
2021
|
Richard Chesworth Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
33,779
-100.0%
|
$2,026,740
$60.12 P/Share
|
|
Aug 27
2021
|
Richard Chesworth Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,779
+50.0%
|
$675,580
$20.0 P/Share
|
|
Aug 19
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+2.52%
|
$24,000
$2.08 P/Share
|
|
Aug 17
2021
|
Richard Chesworth Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
54,000
-75.06%
|
$2,754,000
$51.01 P/Share
|
|
Aug 17
2021
|
Richard Chesworth Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,000
+50.0%
|
$1,080,000
$20.0 P/Share
|
|
Aug 11
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
242,133
-100.0%
|
$14,770,113
$61.0 P/Share
|
|
Aug 11
2021
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
242,133
-100.0%
|
$14,770,113
$61.0 P/Share
|
|
Aug 04
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,037
-0.23%
|
$62,220
$60.03 P/Share
|
|
Aug 04
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,037
+0.23%
|
$2,074
$2.08 P/Share
|
|
Aug 03
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,669
-1.24%
|
$340,140
$60.07 P/Share
|
|
Aug 03
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,669
+1.22%
|
$11,338
$2.08 P/Share
|
|
Aug 02
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,456
-1.65%
|
$1,430,816
$61.23 P/Share
|
|
Aug 02
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,456
+4.7%
|
$46,912
$2.08 P/Share
|
|
Jul 30
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,279
-1.37%
|
$376,740
$60.07 P/Share
|
|
Jul 30
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,279
+1.35%
|
$12,558
$2.08 P/Share
|